CICC Qide (Xiamen) Innovation Biomedical Equity Investment Fund Completes RMB 1.6B+ Fundraising and SEC Filing

VCBeat (WeChat ID: vcbeat) has learned that during the critical phase of the fight against the novel coronavirus pneumonia, encouraging news has emerged from the private equity investment community. The CICC Qide (Xiamen) Innovative Biopharmaceutical Equity Investment Fund (“CICC Qide”), managed by CICC Capital Management Co., Ltd. (“CICC Capital”), has completed its filing, with an initial scale exceeding RMB 1.6 billion.

This fund is the first equity investment fund dedicated to innovative pharmaceuticals launched by a private equity manager affiliated with a Chinese securities company. Its establishment marks a significant breakthrough in CICC Capital’s strategic layout within the biopharmaceutical industry. Leveraging its strong performance track record, brand reputation, and investment management capabilities, CICC Qide has gained recognition and support from numerous renowned fund-of-funds, institutional investors, listed companies, and CICC Wealth Management clients. It successfully completed oversubscription against market trends in a short period, becoming one of the largest RMB-denominated biopharmaceutical funds in terms of scale over the past two years.

Following the outbreak of the epidemic, CICC Qide immediately engaged in close communication and collaboration with multiple innovative pharmaceutical companies slated for investment, facilitating the accelerated R&D and production of nucleic acid testing kits, therapeutic antibodies, antiviral drugs, and vaccines targeting COVID-19. These efforts received high recognition and support from the Asset Management Association of China (AMAC), making CICC Qide the first private equity investment fund to complete registration through the “green channel for filing asset management products related to epidemic prevention and control.”

Amid the pandemic, China’s biopharmaceutical industry has faced significant challenges while also seizing new opportunities for growth. CICC Qide will continue to focus on biopharmaceutical and biotechnology companies with world-leading capabilities, fully capitalizing on investment opportunities arising from policy dividends of China’s healthcare reforms, industrial upgrading in the pharmaceutical sector, and IPO benefits for pharmaceutical enterprises. By systematically leveraging CICC and CICC Capital’s leading advantages—including in-depth healthcare industry research, extensive coverage of high-quality projects, and strong exit capabilities in the capital markets—we aim to contribute to the innovative development of China’s pharmaceutical industry and the health and well-being of the Chinese people in the new decade.